Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...

Op-ed: By investing in a peer workforce, policymakers can help Latinx communities overcome barriers to accessing quality HIV ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

In the complex landscape of chronic health conditions, living with HIV while recovering from a stroke presents a unique set ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

The number of HIV diagnoses in the Netherlands is no longer falling and infections are on the rise among young men, according ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

While the recent study by the Human Sciences Research Council (HSRC) revealed that people living with HIV in KwaZulu-Natal ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...